News Summary
An investigation into the proposed sale of OptiNose, Inc. to Paratek Pharmaceuticals has begun, raising concerns about the fairness of the deal for shareholders. Led by legal experts, the inquiry aims to ensure that OptiNose investors receive the best possible value amid potential undervaluation. Shareholders are encouraged to reach out to attorneys for support as two law firms investigate the legitimacy of the transaction.
Investigation Kicks Off for OptiNose Shareholders in New Orleans
Exciting news is stirring in New Orleans as an investigation has been launched into the proposed sale of OptiNose, Inc. (NASDAQ: OPTN) to Paratek Pharmaceuticals. With a group of experts delving into the details, the goal is to ensure that OptiNose shareholders receive a fair deal.
What’s on the Table?
So, what exactly are the terms of this proposed sale? Well, OptiNose shareholders are looking at a cash payout of $9.00 per share. Additionally, there’s potential for even more funds, as shareholders may snag up to $5.00 per share in contingent value rights, but there’s a catch. Those rights hinge upon reaching certain revenue milestones tied to XHANCE, a product of OptiNose.
Why the Investigation?
Now, you might be wondering why there’s a need for an investigation in the first place. The inquiry, spearheaded by the former Attorney General of Louisiana, seeks to investigate whether the deal is genuinely as beneficial as it sounds. There’s a concern that the proposed payment and the entire sale process could be undervaluing the company. Shareholders want to know if they are getting the best possible value for their investments.
This investigation isn’t just about the numbers; it’s about transparency and fairness. Questions are swirling about whether OptiNose’s board of directors made every effort to secure the optimal consideration for the shareholders. Did they access all the critical information necessary for shareholders to make an informed decision? This is what Kahn Swick & Foti, LLC (KSF) aims to uncover.
Contacting KSF
If you’re an OptiNose shareholder and feel unsure about the fairness of the proposed transaction, there’s a path for you to have your voice heard. You can reach out to KSF Managing Partner Lewis S. Kahn either via email at lewis.kahn@ksfcounsel.com or by giving him a call at (toll-free) 855-768-1857. They also have a dedicated website where you can find more information about the case: https://www.ksfcounsel.com/cases/nasdaqgs-optn/.
No Out-of-Pocket Fees
What’s even more reassuring for shareholders is the fact that Kahn Swick & Foti takes on these types of cases on a contingent fee basis. This means you won’t have to worry about any upfront legal fees or expenses. It’s all about ensuring shareholders have access to the best legal representation without the financial burden hanging over their heads.
Another Player in the Game
But that’s not the only investigation underway! Halper Sadeh LLC, a different law firm specializing in investor rights, is also conducting an inquiry into this transaction. They are focusing on ensuring the fairness of the sale for OptiNose shareholders. Their investigation is similar and aims to determine if there are any breaches of fiduciary duties or violations of federal securities laws involved in this sale.
Shareholders who wish to assess their situation with Halper Sadeh can reach out to Daniel Sadeh and Zachary Halper by calling (212) 763-0060 or email them at sadeh@halpersadeh.com and zhalper@halpersadeh.com.
What’s Next?
As this investigation unfolds, there remains a spotlight on OptiNose and its board of directors. Stakeholders are watching closely to see if they will receive everything they deserve from this proposed deal. With two law firms keeping a close eye, shareholders may find themselves with more support and answers as they navigate this potential transition.
For now, it’s a waiting game for OptiNose shareholders. They’ll want to stay informed and prepared to act as things develop. After all, a deal like this can change the financial landscape, and understanding the ins and outs is crucial for anyone watching their investments in OptiNose closely.
Deeper Dive: News & Info About This Topic
- Business Wire: OPTN Stock Alert
- Eagle Tribune: OPTN Stock Alert
- Business Wire: LGTY Stock Alert
- Business Wire: OPTINOSE INVESTOR ALERT
- Wikipedia: Optinose
